Vascular endothelial growth factor A, a potential non-invasive biomarker for metabolic dysfunction-associated steatotic liver disease progression
These findings suggest that the plasma protein VEGFA may be an effective biomarker for monitoring fibrosis progression in patients with MASLD.
Authors
- Stergios Kechagias (ORCID: https://orcid.org/0000-0001-7614-739X)
- Mathias Liljeblad (ORCID: https://orcid.org/0000-0002-8368-5775)
- Sara Hansson (ORCID: https://orcid.org/0000-0002-9045-0333)
- Mattias Ekstedt (ORCID: https://orcid.org/0000-0002-5590-8601)
- Patrik Nasr (ORCID: https://orcid.org/0000-0002-2928-4188)
- Boxi Zhang (ORCID: https://orcid.org/0000-0002-6446-3747)
- Cecilia Jönsson (ORCID: https://orcid.org/0000-0003-0981-0264)
- Showgy Y. Ma’ayeh (ORCID: https://orcid.org/0000-0001-7091-5570)
Institutions
- Linköping University (SE)
- Olink Bioscience (Sweden) (SE)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Finland) (FI)
Publication Details
- Journal
- Clinical Biochemistry
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.clinbiochem.2025.110920
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00